Compare ACV & AURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ACV | AURA |
|---|---|---|
| Founded | 2015 | 2007 |
| Country | United States | United States |
| Employees | N/A | 106 |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 272.3M | 318.8M |
| IPO Year | N/A | 2021 |
| Metric | ACV | AURA |
|---|---|---|
| Price | $27.35 | $5.03 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $20.20 |
| AVG Volume (30 Days) | 38.8K | ★ 195.7K |
| Earning Date | 01-01-0001 | 11-13-2025 |
| Dividend Yield | ★ 9.20% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $16.82 | $4.35 |
| 52 Week High | $23.74 | $8.27 |
| Indicator | ACV | AURA |
|---|---|---|
| Relative Strength Index (RSI) | 62.65 | 35.98 |
| Support Level | $27.09 | $4.84 |
| Resistance Level | $27.79 | $5.30 |
| Average True Range (ATR) | 0.45 | 0.33 |
| MACD | 0.04 | -0.02 |
| Stochastic Oscillator | 40.29 | 13.33 |
Virtus AllianzGI Diversified Income & Convertible Fund is a diversified, limited-term, closed-end management investment company. The fund's investment objective is to provide total return through a combination of current income and capital appreciation while seeking to provide downside protection against capital loss. It invests in a diversified portfolio of convertible securities, income-producing equity securities, and income-producing debt and other instruments of varying maturities, of which a majority of the managed assets are invested in convertibles.
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.